ANXA7 (annexin A7) is a calcium/phospholipid-binding protein that functions as a multifaceted regulator across diverse physiological processes. Its primary mechanism involves calcium-dependent binding to phospholipids, enabling membrane fusion and exocytosis 1. ANXA7 exhibits tumor suppressor activity, frequently inactivated by genomic deletions at chromosome 10 in prostate, breast, and kidney cancers 1. Loss of ANXA7 disrupts the PTEN-EGFR-PI3K-AKT signaling axis, promoting tumor cell survival 1. Beyond oncology, ANXA7 regulates primordial follicle formation through JAK/STAT3 signaling, with reduced expression associated with premature ovarian insufficiency 2. In endometrial tissues, ANXA7 suppresses prostaglandin E2 production and regulates implantation; its downregulation correlates with recurrent pregnancy loss 3. ANXA7 also promotes trophoblast proliferation via JAK1/STAT3 activation, with reduced expression in preeclampsia 4. In inflammatory contexts, ANXA7 supports autophagy and prevents NLRP3-mediated pyroptosis in intestinal epithelium; RNF168-induced ANXA7 degradation drives Crohn's disease progression 5. Additionally, ANXA7 possesses RNA-binding capacity, particularly through phase separation in neurons, potentially influencing synaptic plasticity 6. Finally, ANXA7 participates in atherosclerosis development by regulating inflammation-related signaling 7.